HHS Finds ‘Questionable Billing’ for Compounded Topical Drugs in Medicare Part D

The HHS Office of Inspector General flagged “questionable billing” and rapid growth in Medicare Part D spending for compounded topical drugs in a report released Thursday.
Source: Drug Industry Daily